{"id":"paroxetine-bupropion","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dry mouth"},{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Sexual dysfunction"},{"rate":null,"effect":"Seizure risk (bupropion component)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Paroxetine is a selective serotonin reuptake inhibitor (SSRI) that blocks serotonin reuptake at the presynaptic neuron, increasing synaptic serotonin availability. Bupropion is a norepinephrine-dopamine reuptake inhibitor (NDRI) that blocks reuptake of norepinephrine and dopamine, complementing the serotonergic effect. Together, they provide broader monoaminergic coverage for treating depression and related mood disorders.","oneSentence":"This combination inhibits serotonin reuptake (paroxetine) and norepinephrine/dopamine reuptake (bupropion) to increase monoamine neurotransmitter levels in the brain.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:59:54.784Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Depression with anhedonia or fatigue"}]},"trialDetails":[{"nctId":"NCT03511118","phase":"","title":"Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants","status":"RECRUITING","sponsor":"Duke University","startDate":"2018-10-04","conditions":"Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI","enrollment":1600},{"nctId":"NCT06997198","phase":"PHASE4","title":"Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities","status":"NOT_YET_RECRUITING","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2026-03-01","conditions":"Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities","enrollment":25},{"nctId":"NCT07328373","phase":"","title":"Neurobiological and Genomic Predictors of Relapse in Depression","status":"RECRUITING","sponsor":"Mehmet Kemal Arikan","startDate":"2025-01-01","conditions":"Healthy, Major Depressive Disorder (MDD)","enrollment":204},{"nctId":"NCT04446039","phase":"","title":"Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-07-04","conditions":"Major Depression","enrollment":370212},{"nctId":"NCT06107829","phase":"PHASE4","title":"Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities","status":"WITHDRAWN","sponsor":"Stephen Ruedrich","startDate":"2025-01","conditions":"Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities","enrollment":""},{"nctId":"NCT02893371","phase":"","title":"Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies","status":"TERMINATED","sponsor":"University of New Mexico","startDate":"2016-09","conditions":"Bipolar Disorder","enrollment":1037352},{"nctId":"NCT04437485","phase":"PHASE2","title":"eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk","status":"COMPLETED","sponsor":"Indiana University","startDate":"2020-10-14","conditions":"Depression, Major Depressive Disorder, Dysthymic Disorder","enrollment":46},{"nctId":"NCT02458690","phase":"PHASE2","title":"eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients","status":"COMPLETED","sponsor":"Indiana University","startDate":"2015-07","conditions":"Depression, Major Depressive Disorder, Dysthymic Disorder","enrollment":216},{"nctId":"NCT05889234","phase":"","title":"Multimodal Magnetic Resonance Imaging-based Study of Electroconvulsive Efficacy Prediction in Adolescents With Depression: a Multicenter Prospective Cohort Study","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2023-11-06","conditions":"Major Depressive Disorder, Magnetic Resonance Imaging, Electroconvulsive Therapy","enrollment":180},{"nctId":"NCT03534063","phase":"NA","title":"Implementing Genomics in Practice (IGNITE): CYP2D6 Genotype-Guided Pain Management in Patients Undergoing Arthroplasty Surgery","status":"COMPLETED","sponsor":"University of Florida","startDate":"2018-06-07","conditions":"Pain, Postoperative","enrollment":260},{"nctId":"NCT05737511","phase":"PHASE4","title":"Efficacy of Hydroxyzine for Patients With Panic Disorder","status":"NOT_YET_RECRUITING","sponsor":"Sultan Qaboos University","startDate":"2023-12-30","conditions":"Panic Disorder","enrollment":80},{"nctId":"NCT00564278","phase":"NA","title":"Effects of Adding Motivational Interviewing to Antidepressant Treatment for Hispanic Adults With Depression","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2008-02","conditions":"Depression","enrollment":217},{"nctId":"NCT00742573","phase":"PHASE2","title":"Incorporating Patient Treatment Choice to Improve Treatment Retention in Depressed Hispanics","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2008-08","conditions":"Major Depressive Disorder","enrollment":170},{"nctId":"NCT01715805","phase":"PHASE3","title":"Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2012-11-15","conditions":"Major Depressive Disorder","enrollment":1022},{"nctId":"NCT01838876","phase":"PHASE3","title":"Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2013-04-29","conditions":"Major Depressive Disorder","enrollment":442},{"nctId":"NCT00429169","phase":"PHASE4","title":"Paroxetine/Bupropion in Suicide Attempters/Ideators With Major Depression","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","startDate":"2004-06","conditions":"Depression","enrollment":101},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":"Dementia, Depression, Schizophrenia","enrollment":407},{"nctId":"NCT02178696","phase":"PHASE4","title":"Predictors of Antidepressant Response","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2011-01","conditions":"Depression","enrollment":44},{"nctId":"NCT01748955","phase":"PHASE4","title":"Paroxetine/Bupropion in Depression With Suicide Attempt or Thoughts: fMRI Study","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2010-06","conditions":"Depression, Suicidal Ideation","enrollment":15},{"nctId":"NCT01916824","phase":"PHASE4","title":"Effects of Treatment on Decision-making in Major Depression","status":"COMPLETED","sponsor":"Emory University","startDate":"2013-08","conditions":"Major Depressive Disorder, Healthy Controls","enrollment":53},{"nctId":"NCT02400346","phase":"PHASE3","title":"Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2015-03","conditions":"Major Depression Disorder","enrollment":132},{"nctId":"NCT01944657","phase":"NA","title":"Supplemental Transcranial Magnetic Stimulation (TMS) vs. Standard Medication Monotherapy for Treating Major Depression: An Exploratory Field Study","status":"WITHDRAWN","sponsor":"Sheppard Pratt Health System","startDate":"2013-09","conditions":"1. Major Depressive Disorder","enrollment":""},{"nctId":"NCT00817011","phase":"NA","title":"Development of Pharmacogenomic Method to Predict Antidepressant Responsiveness","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2006-04","conditions":"Depression, Antidepressant Drug Adverse Reaction","enrollment":1000},{"nctId":"NCT02612142","phase":"NA","title":"Physical EXercise as an Adjunct Treatment for Depression","status":"COMPLETED","sponsor":"Université de Reims Champagne-Ardenne","startDate":"2011-06","conditions":"Major Depressive Disorder","enrollment":48},{"nctId":"NCT00926835","phase":"PHASE4","title":"Effect of Antidepressants on the Treatment for Korean Major Depressive Disorder Patients","status":"TERMINATED","sponsor":"Ministry of Health & Welfare, Korea","startDate":"2009-05","conditions":"Major Depressive Disorder","enrollment":692},{"nctId":"NCT00129467","phase":"NA","title":"Methylphenidate for Depressed Cancer Patients Receiving Palliative Care","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","startDate":"2005-02","conditions":"Depression, Palliative Care, Cancer","enrollment":47},{"nctId":"NCT01896349","phase":"NA","title":"Interpersonal Psychotherapy for Treatment Resistant Depression","status":"UNKNOWN","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2013-04","conditions":"Treatment Resistant Depression","enrollment":74},{"nctId":"NCT00612807","phase":"PHASE1, PHASE2","title":"Treatment of Mood and Marriage Study (TOMMS)","status":"COMPLETED","sponsor":"Duke University","startDate":"2006-07","conditions":"Major Depressive Disorder, Partner Relational Disorder (V61.10)","enrollment":42},{"nctId":"NCT01764867","phase":"PHASE4","title":"Algorithm Guided Treatment Strategies for Major Depressive Disorder","status":"UNKNOWN","sponsor":"Shanghai Mental Health Center","startDate":"2012-06","conditions":"Major Depressive Disorder","enrollment":1080},{"nctId":"NCT01488266","phase":"NA","title":"Aripiprazole Augmentation Versus Switching to Different Class of Antidepressants in Major Depressive Disorder","status":"UNKNOWN","sponsor":"Korea University","startDate":"2011-11","conditions":"Major Depressive Disorder","enrollment":90},{"nctId":"NCT00351910","phase":"PHASE3","title":"Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-05","conditions":"Major Depressive Disorder","enrollment":494},{"nctId":"NCT00704860","phase":"PHASE4","title":"Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism","status":"COMPLETED","sponsor":"University of Ottawa","startDate":"2005-02","conditions":"Major Depression","enrollment":27},{"nctId":"NCT00012558","phase":"NA","title":"Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"1998-09","conditions":"Bipolar Disorder","enrollment":5000},{"nctId":"NCT00177567","phase":"PHASE4","title":"Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2001-07","conditions":"Bipolar Disorder","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Seroxat, wellbutrin"],"phase":"marketed","status":"active","brandName":"Paroxetine+Bupropion","genericName":"Paroxetine+Bupropion","companyName":"Ministry of Health & Welfare, Korea","companyId":"ministry-of-health-welfare-korea","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination inhibits serotonin reuptake (paroxetine) and norepinephrine/dopamine reuptake (bupropion) to increase monoamine neurotransmitter levels in the brain. Used for Major depressive disorder, Depression with anhedonia or fatigue.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}